Positive Topline Results for Breyanzi (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma

Bristol Myers Squibb Announces Positive Topline Results for Breyanzi (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma - Trial met primary endpoint of overall response rate and key secondary endpoint of complete response rate -  With these data, Breyanzi demonstrates efficacy and manageable safety in a fifth cancer type, the most of any CD19-directed CAR T cell therapy

Fonte: BMS Bristol Myers Squibb